Profil
Tami Rachmilewitz worked as the Medical Director & Head-Pharmacovigilance at NeuroDerm Ltd.
from 2016 to 2018.
She then served as the Senior Vice President-Clinical Development at Vascular Biogenics Ltd.
in 2022.
In 2023, she was the Chief Medical Officer at BioLineRx Ltd.
Dr. Rachmilewitz obtained her undergraduate degree from The Hebrew University of Jerusalem and her doctorate from The Hebrew University Hadassah Medical School.
Anciens postes connus de Tami Rachmilewitz
| Sociétés | Poste | Fin |
|---|---|---|
| BIOLINERX LTD. | Directeur Technique/Scientifique/R&D | 01/10/2023 |
| NOTABLE LABS, LTD. | Directeur Technique/Scientifique/R&D | 01/12/2022 |
| NEURODERM LTD | Directeur Technique/Scientifique/R&D | 01/01/2018 |
Formation de Tami Rachmilewitz
| The Hebrew University Hadassah Medical School | Doctorate Degree |
| The Hebrew University of Jerusalem | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOLINERX LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Vascular Biogenics Ltd.
 Vascular Biogenics Ltd. BiotechnologyHealth Technology Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel. | Health Technology |
NeuroDerm Ltd.
 NeuroDerm Ltd. BiotechnologyHealth Technology NeuroDerm Ltd. operates as a clinical-stage pharmaceutical company. It engages in the development of next-generation treatments for central nervous system disorders. The company was founded by Eliahu Heldman on March 18, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
